Activation of EGFR signaling from pilocytic astrocytomas to glioblastomas

Imagem de Miniatura
Arquivos
art_CARVALHO_Activation_of_EGFR_signaling_from_pilocytic_astrocytomas_to_2014.PDF (313.49 KB)
Citações na Scopus
5
Tipo de produção
article
Data de publicação
2014
DOI
Scopus
Web of Science
Título da Revista
ISSN da Revista
Título do Volume
Editora
WICHTIG EDITORE
Autores
Citação
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, v.29, n.2, p.E120-E128, 2014
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Introduction: EGFR analyses allow for better correlation between genotype and phenotype in astrocytomas and represent an attractive therapeutic target. Most studies emphasize analyses of EGFR in glioblastomas (GBMs) but do not analyze all grades of astrocytomas (from pilocytic to GBM). The purpose of our study was to evaluate the status of EGFR (expression, deletion, and amplification) and EGFR protein expression in all grades of astrocytomas. Patients and methods: We analyzed a total of 145 surgical tumor specimens that included: 22 pilocytic astrocytomas, 22 grade II astrocytomas, 17 grade III astrocytomas and 84 GBMs. The specimens were compared to 17 non-neoplastic brain tissues obtained from epilepsy surgery. EGFR expression, EGFR amplification and EGFRvIII analyses were performed by quantitative real-time PCR, and protein expression was evaluated by immunohistochemistry. Results: EGFR relative overexpression and EGFR amplification were observed, respectively, in 50% and 20% of astrocytomas, while EGFRvIII was only found in GBMs (34.5%, p=0.005). Amongst EGFR-amplified GBM cases, 59% also presented EGFRvIII (p<0.001). Cytoplasmic accumulation of EGFR protein was detected in 75% of astrocytomas, and 21% of the astrocytomas showed nuclear localization (p=0.003). Conclusions: EGFR alterations were found in all grades of astrocytomas, from pilocytic to GBMs, while EGFRvIII was exclusively found in GBMs. These findings provide important information on the mechanisms involved in the progression of astrocytomas for determining whether EGFR status can be used for effective and specific therapy.
Palavras-chave
Astrocytomas, EGFR expression, EGFR amplification, EGFRvIII, Glioblastoma, EGFR protein expression
URI
https://observatorio.fm.usp.br/handle/OPI/8641
Referências
  1. Andersson U, 2004, ACTA NEUROPATHOL, V108, P135, DOI 10.1007/s00401-004-0875-6
  2. Arjona D, 2005, NEUROPATH APPL NEURO, V31, P384, DOI 10.1111/j.1365-2990.2005.00653.x
  3. Barbosa KC, 2008, INT J BIOL MARKER, V23, P140
  4. Belda-Iniesta C, 2008, CLIN TRANSL ONCOL, V10, P73, DOI 10.1007/s12094-008-0159-z
  5. Biernat W, 2004, BRAIN PATHOL, V14, P131
  6. Brand Toni M, 2011, Discov Med, V12, P419
  7. Brandes AA, 2008, CLIN CANCER RES, V14, P957, DOI 10.1158/1078-0432.CCR-07-1810
  8. Bredel M, 1999, CLIN CANCER RES, V5, P1786
  9. de la Iglesia N, 2008, GENE DEV, V22, P449, DOI 10.1101/gad.1606508
  10. Dittmann K, 2011, RADIOTHER ONCOL, V99, P317, DOI 10.1016/j.radonc.2011.06.001
  11. Fenton TR, 2012, P NATL ACAD SCI USA, V109, P14164, DOI 10.1073/pnas.1211962109
  12. Haas-Kogan DA, 2005, J NATL CANCER I, V97, P880, DOI 10.1093/jnci/dji161
  13. Hadzisejdic I, 2010, MODERN PATHOL, V23, P392, DOI 10.1038/modpathol.2009.166
  14. Hsu SC, 2009, AM J TRANSL RES, V1, P249
  15. HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577
  16. Huang WC, 2011, J BIOL CHEM, V286, P20558, DOI 10.1074/jbc.M111.240796
  17. Husain H, 2012, LARYNGOSCOPE, V122, P2762, DOI 10.1002/lary.23647
  18. KAMIO T, 1990, HUM PATHOL, V21, P277, DOI 10.1016/0046-8177(90)90227-V
  19. Kersting C, 2004, LAB INVEST, V84, P582, DOI 10.1038/labinvest.3700077
  20. Kuan CT, 2001, ENDOCR-RELAT CANCER, V8, P83, DOI 10.1677/erc.0.0080083
  21. Li C, 2009, ONCOGENE, V28, P3801, DOI 10.1038/onc.2009.234
  22. Liccardi G, 2011, CANCER RES, V71, P1103, DOI 10.1158/0008-5472.CAN-10-2384
  23. LIPPONEN P, 1994, BRIT J CANCER, V69, P1120, DOI 10.1038/bjc.1994.220
  24. Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
  25. Lo HW, 2005, CANCER RES, V65, P338
  26. Lo Hui-Wen, 2010, Curr Mol Pharmacol, V3, P37
  27. Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4
  28. Lv S, 2012, INT J ONCOL, V41, P1029, DOI 10.3892/ijo.2012.1539
  29. Marie Y, 2005, NEUROLOGY, V64, P1444
  30. Marquez A, 2004, DIAGN MOL PATHOL, V13, P1, DOI 10.1097/00019606-200403000-00001
  31. Marti U, 2001, THYROID, V11, P137, DOI 10.1089/105072501300042785
  32. Mellinghoff IK, 2007, CLIN CANCER RES, V13, P378, DOI 10.1158/1078-0432.CCR-06-1992
  33. Mellinghoff IK, 2005, NEW ENGL J MED, V353, P2012, DOI 10.1056/NEJMoa051918
  34. Mitsudomi T, 2010, FEBS J, V277, P301, DOI 10.1111/j.1742-4658.2009.07448.x
  35. Nagane M, 2001, CANC LETT, V162, P17
  36. NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727
  37. Ohgaki H, 2009, CANCER SCI, V100, P2235, DOI 10.1111/j.1349-7006.2009.01308.x
  38. Ohgaki H, 2011, BRAIN TUMOR PATHOL, V28, P177, DOI 10.1007/s10014-011-0029-1
  39. Ohgaki H, 2004, CANCER RES, V64, P6892, DOI 10.1158/0008-5472.CAN-04-1337
  40. Pedersen MW, 2001, ANN ONCOL, V12, P745, DOI 10.1023/A:1011177318162
  41. Psyrri A, 2005, CLIN CANCER RES, V11, P5856, DOI 10.1158/1078-0432.CCR-05-0420
  42. Psyrri A, 2008, CANCER EPIDEM BIOMAR, V6, P1486
  43. Rae JM, 2004, BREAST CANCER RES TR, V87, P87, DOI 10.1023/B:BREA.0000041585.26734.f9
  44. Reardon DA, 2013, CLIN CANCER RES, V19, P900, DOI 10.1158/1078-0432.CCR-12-1707
  45. Reifenberger G, 2004, J MOL MED-JMM, V82, P656, DOI 10.1007/s00109-004-0564-x
  46. Roskoski R, 2004, BIOCHEM BIOPH RES CO, V319, P1, DOI 10.1016/j.bbrc.2004.04.150
  47. Ruano Y, 2009, AM J CLIN PATHOL, V131, P257, DOI 10.1309/AJCP64YBDVCTIRWV
  48. Scrideli CA, 2007, J NEURO-ONCOL, V83, P233, DOI 10.1007/s11060-007-9328-0
  49. Shinojima N, 2003, CANCER RES, V63, P6962
  50. Smith JS, 2001, J NATL CANCER I, V93, P1246, DOI 10.1093/jnci/93.16.1246
  51. Trembath DG, 2007, MOL CANCER, V6, P1
  52. Valente V, 2009, BMC MOL BIOL, V10, P1
  53. van den Bent MJ, 2009, J CLIN ONCOL, V27, P1268, DOI 10.1200/JCO.2008.17.5984
  54. Viana-Pereira M, 2008, ANTICANCER RES, V28, P913
  55. Voelzke WR, 2008, CURR TREAT OPTION ON, V9, P23, DOI 10.1007/s11864-008-0053-5
  56. Voldborg BR, 1997, ANN ONCOL, V8, P1197
  57. Wang SC, 2009, CLIN CANCER RES, V21, P6484
  58. Wang YN, 2012, CELL BIOSCI, V2, DOI 10.1186/2045-3701-2-13
  59. Wanner G, 2008, RADIOTHER ONCOL, V86, P383, DOI 10.1016/j.radonc.2007.10.041
  60. Xia WY, 2009, MOL CARCINOGEN, V48, P610, DOI 10.1002/mc.20504

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - FM/MNE
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - HC/IPq
Carregar mais